又一家CXO公司2025年上半年业绩预喜。 7月24日早间,药明生物(2269.HK)发布业绩预告称,预计与去年同期比较上半年收益增长约16%;上半年利润及归属于公司权益股东的利润相比于去年同期将分别增长约54%和约56%,毛利率将同比提升约3.6%。 对于业绩增长的原因,药明生物称,主要得益于集团扩大了对生物药行业提供包括研究发现、IND前开发及临床和商业化生产等在内的服务范围;多个先进技术...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.